medigraphic.com
SPANISH

Archivos de Cardiología de México

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2003, Number s1

<< Back Next >>

Arch Cardiol Mex 2003; 73 (s1)

Hypertension in Mexico

Rosas PM
Full text How to cite this article

Language: Spanish
References: 9
Page: 137-140
PDF size: 51.02 Kb.


Key words:

National Survey, Cardiovascular risk factors, Hipertension, Diabetes.

ABSTRACT

The 2000 National Health Survey (ENSA 2000) was a probabilistic survey that included more than 45,000 subjects aged between 20 to 69 years old. It was directed to determine the prevalence of non-communicable chronic diseases such as hypertension, diabetes, obesity glucosa, and proteinuria. The survey was weighed with to the National Register of Population (INEGI). The prevalence for hypertension was 30.05%, for diabetes of 10.76%, for obesity 24.4%, abnormal capillary glucose 12.7% and for proteinuria of 9.2%. Using Conjunctive Consolidation Analysis the interrelationship among the non-communicable chronic diseases was demonstrated. The prevalence was directly related with age, and obesity was the most important modifier of the prevalence of non-communicable chronic disease. ENSA 2000 alerts on the urgent need of national strategies to restrain this important national public health problem.


REFERENCES

  1. Cardiovascular Diseases: WHO: http://www. who.int/ncd/cvd/CardioBroch.pdf 2002.

  2. Murray CJL, Lopez AD: Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997; 349: 1269-1276.

  3. Causas de Mortalidad en México 2000. Estadísticas de Mortalidad, Secretaría de Salud: http://www.ssa.gob.mx

  4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach Nh, Eberlein Ka, et al: Blood Pressure, stroke and coronary artery disease. Part 2. Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.

  5. Lenfant C: Reflections of hypertension control rates. Arch Intern Med 2002; 162: 131-132.

  6. Velázquez Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, Attie F, Tapia Conyer R; Grupo Encuesta Nacional de Salud 2000: Hipertensión Arterial en México: Resultados de la ENSA 2000. Arch Cardiol Mex 2002; 72(1): 71-84.

  7. Chalmers J: WHO-ISH Hypertension Guidelines Committee. 1999 World Health organization-International Society of Hypertension: Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-185.

  8. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, Williams K, Gonzalez-Villalpando C, et al: Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension 2002; 39: 203-8.

  9. National High Blood Pressure Education Program, NIH; NHLBI: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Nov 1997; 1-64. http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Arch Cardiol Mex. 2003;73